$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
What is the price of entrectinib after medical insurance reimbursement in 2025?
2026-02-01 22:25:32
Check Details
How much do you need to pay out-of-pocket for acalatinib/acalabrutinib after medical insurance reimbursement?
2026-02-01 22:25:32
Check Details
What are the possible side effects of using ibrutinib/ibrutinib?
2026-02-01 22:25:32
Check Details
How to deal with the most serious side effects of taking Olaparib?
2026-02-01 22:25:32
Check Details
Is it really not possible to stop taking venetoclax at will after taking it?
2026-02-01 22:25:32
Check Details
Has Asiminib been included in the scope of medical insurance reimbursement?
2026-02-01 22:25:32
Check Details
What are the precautions to take while using Ritlecitinib?
2026-02-01 22:25:32
Check Details
What should I pay attention to when using sparsentan? Frequently asked questions from patients when taking medications
2026-02-01 22:25:32
Check Details
How much does a box of Isazomi cost? Drug prices and purchase reference
2026-02-01 22:25:32
Check Details
What is the mechanism of action of rubicatin (rubitin) during treatment? Targeting effect and efficacy analysis
2026-02-01 22:25:32
Check Details
How long does Pralsetinib usually last?
2026-02-01 22:25:32
Check Details
How to combine capmatinib with other targeted drugs
2026-02-01 22:25:32
Check Details
1
2
...
1537
1538
1539
1540
1541
1542
1543
...
10213
10214
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
SKYSCRAPER-02C Study: New Hope for Extensive-Stage Small Cell Lung Cancer Treatment
2
LPCAT3: The Key Player in MASH Progression to Hepatocellular Carcinoma
3
Tucatinib (Tukysa): A Precision Medicine for HER2-Positive Breast & Colorectal Cancer
4
Venetoclax Therapy Guidelines: Balancing Precision Targeting with Risk Management
5
Global Breakthrough: Pralsetinib - Precision Medicine for RET Mutation-Driven Cancers
6
A Comprehensive Guide to Benralizumab Adverse Reactions: Prevention and Management
7
Lemborexant: A Dual Orexin Receptor Antagonist Revolutionizing Insomnia Treatment
8
Breztri Aerosphere Approved by US FDA for Maintenance Treatment of Asthma in Patients Aged 12 Years and Older
9
Datopotamab Deruxtecan as First-Line Treatment for Advanced Triple-Negative Breast Cancer: Full Interpretation of the Phase III TROPION-Breast02 Trial
10
Elacestrant: Precision Therapy for ESR1-Mutant Resistant HR+/HER2- Advanced Breast Cancer
11
Vibegron 2026 Research Updates: New Evidence for Overactive Bladder Treatment
12
Elafibranor for Cholestatic Liver Diseases: Efficacy Maintenance and Drug Resistance Analysis